CTLA4 and hepatocellular carcinoma: In another single center, open-label, randomized phase 2 trial that investigated neoadjuvant nivolumab compared to nivolumab plus ipilimumab (anti-CTLA-4 monoclonal antibody) for one dose prior to surgery in patients with resectable HCC.